Bernard Coulie - 17 Apr 2026 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Reporting relationship: President and CEO, Director
Issuer ticker: PLRX
Reported as of: 17 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Apr 2026, 16:42:38 UTC
Prior SEC filing: 26 Jan 2026
Next SEC filing: 30 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Woo, attorney-in-fact

Key filing fact

Bernard Coulie filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 17 Apr 2026.

Key facts

This page summarizes Bernard Coulie's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
14 reported transactions and 14 derivative rows are listed below.
Accepted by SEC: 17 Apr 2026, 16:42.

Change

Previous filing in this sequence was filed on 26 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001808895 Primary reporting owner

Coulie Bernard

Relationship: President and CEO, Director
Address: C/O PLIANT THERAPEUTICS, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO
Signature: /s/ Jennifer Woo, attorney-in-fact
Signature date: 17 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLRX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -146,841
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 146,841
Exercise price: $2.08
Footnotes: F1, F2, F3

PLRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +146,841
Change %
Price: $0.000000^*
Shares after: 146,841
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 146,841
Exercise price: $1.33
Footnotes: F1, F2, F3, F4, F5

PLRX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -327,262
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 327,262
Exercise price: $6.22
Footnotes: F1, F2, F6

PLRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +327,262
Change %
Price: $0.000000^*
Shares after: 327,262
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 327,262
Exercise price: $1.33
Footnotes: F1, F2, F4, F5, F6

PLRX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -250,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $26.50
Footnotes: F1, F2, F7

PLRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +250,000
Change %
Price: $0.000000^*
Shares after: 250,000
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $1.33
Footnotes: F1, F2, F4, F5, F7

PLRX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -440,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 440,000
Exercise price: $11.86
Footnotes: F1, F2, F8

PLRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +440,000
Change %
Price: $0.000000^*
Shares after: 440,000
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 440,000
Exercise price: $1.33
Footnotes: F1, F2, F4, F5, F8

PLRX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -206,300
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 206,300
Exercise price: $34.65
Footnotes: F1, F2, F9

PLRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +206,300
Change %
Price: $0.000000^*
Shares after: 206,300
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 206,300
Exercise price: $1.33
Footnotes: F1, F2, F4, F5, F9

PLRX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -256,300
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 256,300
Exercise price: $17.44
Footnotes: F1, F2

PLRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +256,300
Change %
Price: $0.000000^*
Shares after: 256,300
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 256,300
Exercise price: $1.33
Footnotes: F1, F2, F4, F5

PLRX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -325,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 325,000
Exercise price: $11.14
Footnotes: F1, F2

PLRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +325,000
Change %
Price: $0.000000^*
Shares after: 325,000
Date: 17 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 325,000
Exercise price: $1.33
Footnotes: F1, F2, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged.

Footnote F2

The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates.

Footnote F3

The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029.

Footnote F4

The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan).

Footnote F5

The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan).

Footnote F6

The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030.

Footnote F7

The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031.

Footnote F8

The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032.

Footnote F9

The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033.